Business
Treace Medical Concepts Reports Fourth Quarter and Full-Year 2025 Financial Results
PONTE VEDRA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the fourth quarter and full-year ended December 31, 2025. Recent Highlights Generated revenue of $62.5 million in fourth quarter 2025 and revenue of $212.7 million for the full-year 2025, an increase of 2% c
About this update from Treace Medical Concepts, Inc.
[{"type":"image","alt":"Treace Medical Concepts, Inc.","displaySize":"","headline":null,"caption":"Treace Medical Concepts, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":60,"url":"https://media.zenfs.com/en/globenewswire.com/d629ef51169cbf34a252b8eca6fa7363"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vLorRmISLl3PfaqwwnfXfQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg0O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/d629ef51169cbf34a252b8eca6fa7363","width":300,"height":60}},"lazy":false},{"type":"text","content":"PONTE VEDRA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the fourth quarter and full-year ended December 31, 2025.","length":370,"tagName":"p"},{"type":"text","content":"Recent Highlights","length":17,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Generated revenue of $62.5 million in fourth quarter 2025 and revenue of $212.7 million for the full-year 2025, an increase of 2% compared to the prior year.","length":157,"tagName":"p"}]},{"val":[{"type":"text","content":"Reported fourth quarter 2025 net loss of $(9.4) million and adjusted EBITDA of $6.2 million in the fourth quarter 2025. Reported full-year 2025 net loss of $(59.0) million compared to a full-year net loss of $(55.7) million in 2024, reduced adjusted EBITDA loss by 64% to $(3.9) million in the full-year 2025 compared to $(11.0) million in the same period in 2024.","length":364,"tagName":"p"}]},{"val":[{"type":"text","content":"Reduced cash usage by 46% to $27.3 million in full year 2025 compared to $50.5 million in full year 2024.","length":105,"tagName":"p"}]},{"val":[{"type":"text","content":"Increased net new active surgeons by 202 for full-year 2025 and ended the year with 3,337 active surgeons, a 6% increase compared to the prior year and 33% of the estimated 10,000 U.S. surgeons performing bunion surgery.","length":220,"tagName":"p"}]},{"val":[{"type":"text","content":"Broadened global patent portfolio now totaling 135 granted patents in addition to 199 pending patent applications.","length":114,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,...